BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 25456893)

  • 21. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
    Biagi M; Vialichka A; Jurkovic M; Wu T; Shajee A; Lee M; Patel S; Mendes RE; Wenzler E
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
    Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
    Doymaz MZ; Karaaslan E
    Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro susceptibility of tigecycline against multidrug-resistant gram-negative strains: Etest versus agar dilution.
    Özkök S; Togan T; Yesilkaya A; Timurkaynak F; Azap ÖK; Arslan H
    Chemotherapy; 2014; 60(3):151-6. PubMed ID: 25791941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].
    Akin FE; Bayram A; Balci I
    Mikrobiyol Bul; 2010 Apr; 44(2):203-10. PubMed ID: 20549954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
    Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
    Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
    Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
    [No Abstract]   [Full Text] [Related]  

  • 28. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
    Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
    Timurkaynak F; Arslan H; Azap OK; Senger SS; Başaran O; Karaman SO; Haberal M
    Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
    Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):217-21. PubMed ID: 23522845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country.
    Araj GF; Ibrahim GY
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):411-5. PubMed ID: 18814990
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Morrissey I; Olesky M; Hawser S; Lob SH; Karlowsky JA; Corey GR; Bassetti M; Fyfe C
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
    Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM
    Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
    Vouillamoz J; Moreillon P; Giddey M; Entenza JM
    J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.